Lauren A Borch1,2, Jillian Parboosingh3,4,5, Mary Ann Thomas3,4,6, Pamela Veale3,6. 1. Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. lauren.borch@ahs.ca. 2. Department of Medical Genetics, Alberta Children's Hospital, Calgary, AB, Canada. lauren.borch@ahs.ca. 3. Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 4. Department of Medical Genetics, Alberta Children's Hospital, Calgary, AB, Canada. 5. Genetics & Genomics-Molecular Diagnostic Laboratory South, Alberta Public Laboratories, Calgary, AB, Canada. 6. Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada.
Abstract
PURPOSE: Evaluate whether fragile X syndrome (FXS) testing should be transitioned to a second-tier test in global developmental delay, intellectual disability, and autism spectrum disorder in the absence of family history and suggestive clinical features. METHODS: Determine the diagnostic yield of FXS testing performed by the Alberta Children's Hospital (ACH) Molecular Diagnostic Laboratory between 2012 and 2017. Retrospective chart review of FXS-positive patients to determine presence or absence of suggestive clinical features and family history. RESULTS: Of the 2486 pediatric patients with neurodevelopmental disorders tested for FXS, 25 males and 5 females were positive. This corresponds to a 1.2% diagnostic yield of FXS testing at our center. Retrospective chart review of the FXS-positive cases revealed that 96% of FXS patients had either, if not both, clinical features or family history suggestive of FXS present at the time of testing. Only one patient had neither family history nor clinical features suggestive of FXS. CONCLUSION: In 96% of FXS-positive cases, there was sufficient clinical suspicion raised on the basis of clinical features and/or family history to perform targeted FXS testing. We thus propose that in the absence of suggestive clinical features or family history, FXS testing should be transitioned to a second-tier test in neurodevelopmental disorders.
PURPOSE: Evaluate whether fragile X syndrome (FXS) testing should be transitioned to a second-tier test in global developmental delay, intellectual disability, and autism spectrum disorder in the absence of family history and suggestive clinical features. METHODS: Determine the diagnostic yield of FXS testing performed by the Alberta Children's Hospital (ACH) Molecular Diagnostic Laboratory between 2012 and 2017. Retrospective chart review of FXS-positive patients to determine presence or absence of suggestive clinical features and family history. RESULTS: Of the 2486 pediatric patients with neurodevelopmental disorders tested for FXS, 25 males and 5 females were positive. This corresponds to a 1.2% diagnostic yield of FXS testing at our center. Retrospective chart review of the FXS-positive cases revealed that 96% of FXS patients had either, if not both, clinical features or family history suggestive of FXS present at the time of testing. Only one patient had neither family history nor clinical features suggestive of FXS. CONCLUSION: In 96% of FXS-positive cases, there was sufficient clinical suspicion raised on the basis of clinical features and/or family history to perform targeted FXS testing. We thus propose that in the absence of suggestive clinical features or family history, FXS testing should be transitioned to a second-tier test in neurodevelopmental disorders.
Authors: Francisco Martinez-Granero; Fiona Blanco-Kelly; Carolina Sanchez-Jimeno; Almudena Avila-Fernandez; Ana Arteche; Ana Bustamante-Aragones; Cristina Rodilla; Elvira Rodríguez-Pinilla; Rosa Riveiro-Alvarez; Saoud Tahsin-Swafiri; Maria Jose Trujillo-Tiebas; Carmen Ayuso; Marta Rodríguez de Alba; Isabel Lorda-Sanchez; Berta Almoguera Journal: NPJ Genom Med Date: 2021-03-25 Impact factor: 8.617
Authors: Ana Arteche-López; Maria José Gómez Rodríguez; Maria Teresa Sánchez Calvin; Juan Francisco Quesada-Espinosa; Jose Miguel Lezana Rosales; Carmen Palma Milla; Irene Gómez-Manjón; Irene Hidalgo Mayoral; Rubén Pérez de la Fuente; Arancha Díaz de Bustamante; María Teresa Darnaude; Belén Gil-Fournier; Soraya Ramiro León; Patricia Ramos Gómez; Olalla Sierra Tomillo; Alexandra Juárez Rufián; Maria Isabel Arranz Cano; Rebeca Villares Alonso; Pablo Morales-Pérez; Alejandro Segura-Tudela; Ana Camacho; Noemí Nuñez; Rogelio Simón; Marta Moreno-García; Maria Isabel Alvarez-Mora Journal: Genes (Basel) Date: 2021-04-12 Impact factor: 4.096
Authors: Pia Zacher; Thomas Mayer; Frank Brandhoff; Tobias Bartolomaeus; Diana Le Duc; Martin Finzel; Anja Heinze; Susanne Horn; Chiara Klöckner; Gudrun Körber; Julia Hentschel; Malgorzata Kalita; Ilona Krey; Marina Nastainczyk-Wulf; Konrad Platzer; Johannes Rebstock; Bernt Popp; Mathias Stiller; Anne-Christin Teichmann; Rami Abou Jamra; Johannes R Lemke Journal: Genet Med Date: 2021-04-28 Impact factor: 8.822